◆ FUNDING DATA
- Amount
- $25.0M
- Location
- Glasgow, United Kingdom
- Priority score
- 50/100
- Confidence
- 65/100
Investors
Thairm Bio · Scottish National Investment Bank
EBX-102-02 is an orally delivered, full-spectrum microbiome therapeutic in clinical development for irritable bowel syndrome (IBS) and other gastrointestinal diseases.
Thairm Bio · Scottish National Investment Bank